Linzess and Pulmozyme drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Linzess (linaclotide) and Pulmozyme (dornase alfa). Common drug interactions include dysarthria among females and infective pulmonary exacerbation of cystic fibrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Linzess and Pulmozyme. It is created by eHealthMe based on reports of 95 people who take the same drugs from the FDA, and is updated regularly.

What is Linzess?

Linzess has active ingredients of linaclotide. It is often used in constipation. eHealthMe is studying from 24,086 Linzess users. Check the latest studies of Linzess.

What is Pulmozyme?

Pulmozyme has active ingredients of dornase alfa. It is often used in cystic fibrosis. eHealthMe is studying from 20,012 Pulmozyme users. Check the latest studies of Pulmozyme.



On Jul, 20, 2026

95 people who take Linzess and Pulmozyme together, and have interactions are studied.

Linzess and Pulmozyme drug interactions.

What are the common drug interactions of Linzess and Pulmozyme, by gender? *:

female:

  1. Dysarthria (speech disorder)
  2. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
  3. Flatulence (flatus expelled through the anus)
  4. Gastric disorder (disease of stomach)
  5. Human chorionic gonadotropin decreased
  6. Hypertrichosis (hair growth on the body in an amount considered abnormal)
  7. Hypoaesthesia (reduced sense of touch or sensation)
  8. Insulin resistance
  9. Irritability
  10. Lethargy (tiredness)

male:

  1. Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
  2. Abdominal pain upper
  3. Carbon dioxide increased
  4. Cardiac disorder
  5. Diarrhoea
  6. Dyspepsia (indigestion)
  7. Electrolyte imbalance
  8. Fluid retention (an abnormal accumulation of fluid in the blood)
  9. Gastrointestinal disorder (functional problems of gastrointestinal tract)
  10. Nausea (feeling of having an urge to vomit)

What are the common drug interactions of Linzess and Pulmozyme, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Abortion spontaneous (naturally occurring miscarriage)
  2. Human chorionic gonadotropin decreased
  3. Lung disorder (lung disease)
  4. Pneumonia
  5. Pyrexia (fever)
  6. Surgery

20-29:

  1. Fatigue (feeling of tiredness)
  2. Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
  3. Hospitalisation
  4. Abdominal discomfort
  5. Abdominal pain upper
  6. Anxiety
  7. Depression
  8. Headache (pain in head)
  9. Insomnia (sleeplessness)
  10. Oropharyngeal pain

30-39:

  1. Depression
  2. Abdominal discomfort
  3. Aphasia (damage to the parts of the brain that control language)
  4. Asthenia (weakness)
  5. Delusion (a false belief or opinion)
  6. Disturbance in attention
  7. Fatigue (feeling of tiredness)
  8. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  9. Lung disorder (lung disease)
  10. Muscle fatigue (a condition in which muscles cannot exert their normal force)

40-49:

  1. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  2. Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
  3. Influenza
  4. Abdominal pain lower
  5. Cough
  6. Gastric disorder (disease of stomach)
  7. Hyperkalaemia (damage to or disease of the kidney)
  8. Lung disorder (lung disease)
  9. Lung transplant
  10. Oedema peripheral (superficial swelling)

50-59:

  1. Infective pulmonary exacerbation of cystic fibrosis (severe infective lung disease with production of abnormally thick mucus)
  2. Carbon dioxide increased
  3. Hospitalisation

60+:

  1. Dehydration (dryness resulting from the removal of water)
  2. Gastrointestinal disorder (functional problems of gastrointestinal tract)
  3. Infection
  4. Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)

What are the existing conditions these people have? *

  1. Cystic Fibrosis Lung (fibrosis with cyst in the lung): 6 people, 6.32%

* Approximation only. Some reports may have incomplete information.

Do you take Linzess and Pulmozyme?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Linzess and Pulmozyme:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Linzess:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pulmozyme:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Linzess and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pulmozyme and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on linaclotide and dornase alfa (the active ingredients of Linzess and Pulmozyme, respectively), and Linzess and Pulmozyme (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: